Scarlet fever

Summary

Scarlet fever (MONDO:0005952) is a disease. A subtype of streptococcal infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	scarlet fever
Mondo ID	MONDO:0005952
EFO	EFO:0007477
MeSH	D012541
Orphanet	688995
DOID	DOID:8596
ICD-10-CM	A38
ICD-11	107294155
NCIT	C94575
SNOMED CT	30242009
UMLS	C0036285
MedGen	11327
GARD	0027349
Is cancer (heuristic)	no

Also known as: scarlatina

Disease family

This is a subtype of streptococcal infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › gram-positive bacterial infections › streptococcal infection › scarlet fever

Related subtypes (7): erysipelas, streptococcal meningitis, impetigo, pneumococcal infection, streptococcal toxic-shock syndrome, streptococcal sore throat, group B streptococcal infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Penicillin V	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.